Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 4/20 | 0.66 |
| ▸ | GAA | P10253 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14470092 | 0.90 | MEN1 (0.81) | MEN1KMT2AALDH1A1HSD17B10TSHR | |
| SCHEMBL14821411 | 0.86 | MEN1 (0.75) | MEN1KMT2AALDH1A1HSD17B10TSHR | |
| SCHEMBL14470115 | 0.86 | MEN1 (0.75) | MEN1KMT2AALDH1A1HSD17B10TSHR | |
| SCHEMBL15423952 | 0.86 | MEN1 (0.76) | MEN1KMT2AALDH1A1HSD17B10TSHR | |
| SCHEMBL5915300 | 0.86 | MEN1 (0.75) | MEN1KMT2AALDH1A1HSD17B10TSHR | |
| SCHEMBL17628468 | 0.82 | KMT2A (0.70) | MEN1KMT2AALDH1A1HSD17B10TSHR | |
| SCHEMBL13743135 | 0.82 | MEN1 (0.58) | MEN1KMT2AALDH1A1HSD17B10TSHR | |
| SCHEMBL29025657 | 0.82 | MEN1 (0.52) | MEN1KMT2AALDH1A1HSD17B10TSHR | |
| SCHEMBL10795112 | 0.81 | MEN1 (0.56) | MEN1KMT2AALDH1A1TSHRGAA | |
| SCHEMBL14469937 | 0.81 | MEN1 (0.67) | MEN1KMT2AALDH1A1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116143688-B | Preparation method of 3-piperidone compound | 江南大学 | 2025-03-11 | — | — | CN | disclosed |
| CN-116143688-A | Preparation method of 3-piperidone compound | 江南大学 | 2023-05-23 | — | — | CN | disclosed |
| US-8263808-B2 | Method for deprotecting aryl or alkyl sulfonamides of primary or secondary amines | SIGNA CHEMISTRY, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263808-B2 | Method for deprotecting aryl or alkyl sulfonamides of primary or secondary amines | SIGNA CHEMISTRY, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263808-B2 | Method for deprotecting aryl or alkyl sulfonamides of primary or secondary amines | SIGNA CHEMISTRY, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20090306391-A1 | METHOD FOR DEPROTECTING ARYL OR ALKYL SULFONAMIDES OF PRIMARY OR SECONDARY AMINES | SIGNA CHEMISTRY, LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306391-A1 | METHOD FOR DEPROTECTING ARYL OR ALKYL SULFONAMIDES OF PRIMARY OR SECONDARY AMINES | SIGNA CHEMISTRY, LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306391-A1 | METHOD FOR DEPROTECTING ARYL OR ALKYL SULFONAMIDES OF PRIMARY OR SECONDARY AMINES | SIGNA CHEMISTRY, LLC (US) | 2009-12-10 | — | — | US | disclosed |
| EP-2035465-A2 | METHOD FOR DEPROTECTING ARYL OR ALKYL SULFONAMIDES OF PRIMARY OR SECONDARY AMINES | SIGNA CHEMISTRY LLC (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007095276-A2 | METHOD FOR DEPROTECTING ARYL OR ALKYL SULFONAMIDES OF PRIMARY OR SECONDARY AMINES | SIGNA CHEMISTRY, LLC (US) | 2007-08-23 | — | — | WO | disclosed |
| US-7250444-B2 | Pyrrole-based HMG-CoA reductase inhibitors | PFIZER INC. (US) | 2007-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306391-A1 | METHOD FOR DEPROTECTING ARYL OR ALKYL SULFONAMIDES OF PRIMARY OR SECONDARY AMINES | ARSA, KCNJ1, SIK3 | MEN1 2135/4885KMT2A 73/4885ALDH1A1 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.